In vivo Imaging with a Fundus Camera in a Rat Model of Laser-Induced Choroidal Neovascularization

2014 ◽  
Vol 231 (2) ◽  
pp. 117-123 ◽  
Author(s):  
Alexander Cunea ◽  
Johanna Meyer ◽  
Christoph Russmann ◽  
Kai Licha ◽  
Pia Welker ◽  
...  
Author(s):  
Qi Qi ◽  
Matthew S. Fox ◽  
Heeseung Lim ◽  
Robert Bartha ◽  
Timothy J. Scholl ◽  
...  
Keyword(s):  

2014 ◽  
Vol 55 (10) ◽  
pp. 6204 ◽  
Author(s):  
Johanna Meyer ◽  
Alexander Cunea ◽  
Dagmar Sonntag-Bensch ◽  
Pia Welker ◽  
Kai Licha ◽  
...  

Biology Open ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. bio048736 ◽  
Author(s):  
Shan Liu ◽  
Antje K. Biesemeier ◽  
Alexander V. Tschulakow ◽  
Harsh V. Thakkar ◽  
Sylvie Julien-Schraermeyer ◽  
...  

ABSTRACTVascular endothelial growth factor (VEGF) is a crucial stimulator for choroidal neovascularization (CNV). Our aim was to develop a reproducible and valid treatment-naive quiescent CNV (i.e. without signs of exudation and with normal visual acuity) rat model by subretinal injection of an adeno-associated virus (AAV)-VEGFA165 vector. The CNV development was longitudinally followed up in vivo by scanning laser ophthalmoscopy/optical coherence tomography, fluorescein and Indocyanine Green angiographies and ex vivo by electron microscopy (EM) and immunohistochemistry. In total, 57 eyes were analysed. In vivo, a quiescent CNV was observed in 93% of the eyes 6 weeks post-transduction. In EM, CNV vessels with few fenestrations, multi-layered basement membranes and bifurcation of endothelial cells were observed sharing the human CNV features. Human VEGF overexpression, multi-layered retinal pigment epithelium (RPE) (RPE65) and macrophages/activated microglia (Iba1) were also detected. In addition, 19 CNV eyes were treated for up to 3 weeks with bevacizumab. The retinal and CNV lesion thickness decreased significantly in bevacizumab-treated CNV eyes compared with untreated CNV eyes 1 week after the treatment. In conclusion, our experimental CNV resembles those seen in patients suffering from treatment-naive quiescent CNV in wet age-related macular degeneration (AMD), and responds to short-term treatment with bevacizumab. Our new model can, therefore, be used to test the long-term effect of new drugs targeting CNV under precisely-defined conditions.


2015 ◽  
Vol 33 (7) ◽  
pp. 1034-1038 ◽  
Author(s):  
Kazuhide Inage ◽  
Yoshihiro Sakuma ◽  
Kazuyo Yamauchi ◽  
Akiko Suganami ◽  
Sumihisa Orita ◽  
...  

NeuroImage ◽  
2007 ◽  
Vol 37 (4) ◽  
pp. 1112-1121 ◽  
Author(s):  
Abesh Kumar Bhattacharjee ◽  
Lindsey M. Meister ◽  
Lisa Chang ◽  
Richard P. Bazinet ◽  
Laura White ◽  
...  

Radiology ◽  
2012 ◽  
Vol 265 (2) ◽  
pp. 418-425 ◽  
Author(s):  
Mark D. Lingwood ◽  
Ting Ann Siaw ◽  
Napapon Sailasuta ◽  
Osama A. Abulseoud ◽  
Henry R. Chan ◽  
...  

2014 ◽  
Vol 15 (4) ◽  
pp. S49
Author(s):  
K. Vasudeva ◽  
S. Patel ◽  
M. Saleem ◽  
A. Balducci ◽  
T. Hitchens ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. e92765 ◽  
Author(s):  
Hongyoon Choi ◽  
Yu Kyeong Kim ◽  
So Won Oh ◽  
Hyung-Jun Im ◽  
Do Won Hwang ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document